VEGFA and non-small cell lung carcinoma: Some researchers have incorporated in their prognostic models with treatments such as chemotherapy [10–12], chemotherapy in combination with vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitor (TKI) [7], and epidermal growth factor receptor (EGFR)-TKI.[13–15] Nonetheless, those models are limited by a lack of information pertaining to the patients’ EGFR molecular profile, which has been firmly proved to have a significant impact on the overall survival (OS) and progression-free survival (PFS) of NSCLC patients.[16–18]